Advanced Solid Tumor Clinical Trial
Official title:
Phase I Trial of Intratumoral Injection of an Adenovirus Encoding Human Endostatin for Advanced Solid Tumors
The growth and metastasis of solid tumors are dependent on angiogenesis. Endostatin, the C-terminal proteolytic fragment of collagen XVIII, is an effective endogenous angiogenesis inhibitor in cancer therapy in mice. Applied for clinical studies in solid tumor, however, recombinant human endostatin protein, difficulties in a large-scale production of the recombinant endostatin protein, and the cumbersome daily administration. Up to now, its clinical application has been hampered by those matters. We herein constructed a adenoviral vector ecoding human endostatin. This study will test the safety and efficacy of recombinant human endostatin adenovirus (Ad-rhE) in the treatment of patients with advanced solid tumors.
It is widely recognized that angiogenesis not only is important in physiological processes
such as embryonic development, wound healing, and organ and tissue regeneration, but also
play a pivotal role in tumor growth, tissue invasion, and metastasis.1 This complex,
multistep process of angiogenesis involves interactions between tumor cells and endothelial
cells (ECs), growth factors, and extracellular matrix components. Tumors that are unable to
elicit angiogenesis exist in a dormant state, and are unable to grow beyond the size of 1-2
mm. Angiogenesis is regulated by a variety of pro-angiogenesis and anti-angiogenesis factors
and their imbalance can lead to disease. The abnormal features of the tumor vasculature
perhaps represent an imbalanced expression of proangiogenic factors and antiangiogenic
factors.1 Antiangiogenic therapies inhibit the growth of genetically stable endothelial
cells, and most tumors should starve to death with little acquired resistance.
Antiangiogenesis agents such as Avastin for the treatment of cancer have now been approved
by the FDA in the US and in other countries.2 Endostatin, a 20 kDa C-terminal fragment of
the carboxyterminus of collagen XVIII, has been shown to block endothelial cell
proliferation, survival, and migration, in part through downregulating proangiogenic factor
(such as Ids, HIF-1a, VEGF-A, bFGF) and upregulating antiangiogenic factors (such as
Thrombospondin-1,2, vasostatin, kininogen).4,5,6 Of the endogenous antiangiogenic factors in
the body, endostatin has broadest anti-cancer spectrum and the least toxic and no resistance
anti-cancer drug in mice and human. Endostatin is the first endogenous angiogenesis
inhibitor to introduce into human clinical trials.
However, therapy with recombinant endostatin protein is hampered by their shot half-life,
difficulties in protein production and long-term storage of bioactive protein. Furthermore,
the inhibition of tumor angiogenesis is a long-term and chronic process of treatment. Gene
therapy may be overcome these difficulties by introducing human endostatin cDNA into the
host and using the body as an endogenous factory to generate highly bioactive gene product.
Expression of endostatin by adenoviral gene transfer (Ad-rhEndo, E10A) generates a strong
systemic therapeutic effect in several models of solid tumors in mice.7,8,9,10 Intratumoral
injections of E10A into subcutaneous xenografts of hepatocellular carcinoma BEL-7402,
nasopharyngeal carcinoma CNE-2, Tongue cancer Tca8113 in nude mice demonstrated significant
tumor growth inhibition and reduce angiogenesis in tumors. No toxic effects of E10A
administration in these pharmacology studies were identified. On the base of promising
preclinical results in solid tumors, we undertook a dose-escalation phase I trial of E10A in
the treatment of patients with advanced solid tumors.
;
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06223308 -
A Study Evaluating the Safety and Efficacy of HB0028 in Subjects With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT05508100 -
Dose Confirmation and Dose Expansion Phase 1 Study of IO-108 and IO-108 + Anti-PD-1 in Solid Tumors
|
Phase 1 | |
Not yet recruiting |
NCT05515185 -
B7-H3 Targeting CAR-T Cells Therapy for B7-H3 Positive Solid Tumors
|
Early Phase 1 | |
Recruiting |
NCT05094804 -
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
|
Phase 1/Phase 2 | |
Completed |
NCT02836600 -
A Study of LY3039478 in Japanese Participants With Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT04890613 -
Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation
|
Phase 1 | |
Recruiting |
NCT04390737 -
Evaluate the Safety and Clinical Activity of HH2853
|
Phase 1/Phase 2 | |
Recruiting |
NCT06007482 -
A Study of ES009 in Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05981703 -
A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors
|
Phase 1 | |
Completed |
NCT04108676 -
Effect of Omeprazole on PK of Fluzoparib in Healthy Male Subjects
|
Phase 1 | |
Recruiting |
NCT05798611 -
Study of ART0380 in Patients With Biologically Selected Solid Tumors
|
Phase 2 | |
Recruiting |
NCT05076396 -
PM14 Administered Intravenously to Patients With Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT06054932 -
Safety, Tolerability, and Immunogenicity of LK101 Alone in Participants With Incurable Solid Tumors
|
Phase 1 | |
Recruiting |
NCT06008366 -
A Phase 1/2 Study of 7MW3711 in Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT04825392 -
A Phase Ib Study of HX008 in Patients With Advanced Solid Tumors
|
Phase 1 | |
Active, not recruiting |
NCT04242199 -
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors
|
Phase 1 | |
Not yet recruiting |
NCT06365918 -
Study of VG2025 Delivered Intraperitoneally in Patients With Advanced Solid Tumors With Carcinomatosis
|
Phase 1 | |
Recruiting |
NCT05461287 -
Safety, Tolerability and Pharmacokinetics Study of QLS31904 in Patients With Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05443126 -
A Study of EP0031 in Patients With Advanced RET-altered Malignancies
|
Phase 1/Phase 2 | |
Recruiting |
NCT05569057 -
A Phase I Trial of SIM1811-03 in Subjects With Advanced Solid Tumors and Cutaneous T-cell Lymphoma
|
Phase 1 |